21 results about "Molecular biomarker" patented technology

A method for characterizing disease activity in a systemic lupus erythematosus patient (SLE), comprising obtaining a dataset associated with a blood, serum, plasma or urine sample from the patient, assessing the dataset for a presence or an amount of protein expression of at least one innate serum or plasma mediator, assessing the dataset for a presence or an amount of protein expression of at least one adaptive serum or plasma mediator biomarker, assessing the dataset for a presence or an amount of at least one chemokine / adhesion molecule biomarker, assessing the dataset for a presence or an amount of at least one soluble TNF superfamily biomarker, assessing the dataset for a presence or an amount of at least one inflammatory mediator biomarker, assessing the dataset for a presence or an amount at least one SLE-associated autoantibody specificity biomarker and calculating a Lupus Disease Activity Immune Index (LDAII) score.

A diagnostic imaging assistance device 1 comprises: a first acquisition unit 10 for acquiring an image of a head through MRI; an image processing unit 11 for extracting a region containing information on a lesion site and the periphery of the lesion site from the acquired image of the head and generating a first image having the extracted region; an extraction unit 12 for extracting a predetermined image feature amount from the first image; a classification unit 14 for determining, on the basis of the image feature amount extracted by the extraction unit 12, the presence or absence of a molecular biomarker associated with the lesion site for classification using a pre-constructed classifier; and a presentation unit 15 for presenting assistance information related to whether or not the lesion site contained in the image of the head has the molecular biomarker, on the basis of the result of the classification by the classification unit 14.

Integrated platforms, systems, and associated processes for measuring lifespan, body size and shape, activity, pathology, pigmentation / color, and multiple in vivo molecular biomarkers using multiple cameras are described. The integrated platform includes a plate and trays supported on the plate. Each tray can hold animals. The integrated platform also includes an imaging module with a first camera and a second camera. The first camera can capture first images associated with movement of the animals and the second camera can capture second images and third images associated with biomarkers of the animals.

The invention discloses a colorectal cancer liver metastasis detection method and system based on multi-omics deep learning, and the method comprises the steps: extracting a characteristic gene group with CRC metastasis-metabolism dual functions, and on the basis of constructing a CRC metastasis risk prediction model, screening molecular markers with CRC metastasis general and CRLM specific characteristics based on the analysis of CRC metastasis risk probability, the biomarker is used as an initial candidate biomarker; meanwhile, a CRLM patient sample and differential expression metabolites corresponding to an LCRC patient sample metabolome are obtained from a metabolome, and a CRLM multilayer core metabolic network is constructed in combination with enrichment pathway analysis of a transcriptome and the metabolome, so that core biomarkers are screened for accurate detection of colorectal cancer liver metastasis; the whole method can effectively screen the biomarker beneficial to detection of colorectal cancer liver metastasis.

The present invention includes a method of characterizing disease activity in a systemic lupus erythematosus patient (SEE), comprising: obtaining a dataset associated with a blood, serum, plasma or urine sample from the patient, wherein the dataset comprises data representing the level of one or more biomarkers in the blood, serum, plasma or urine sample from each of (b) to (g); at least one innate serum or plasma mediator biomarker; at least one adaptive serum or plasma mediator; at least one chemokine / adhesion molecule biomarker; at least one soluble TNF superfamily biomarker; the inflammatory mediator biomarker SCF; at least one SLE-associated autoantibody specificity biomarker; and calculating a Lupus Disease Activity Immune.

The present disclosure relates generally to the field of medical oncology and, in particular, to methods and kits for identifying and treating neuroendocrine carcinomas, such as small cell neuroendocrine (SCN) tumors. Certain aspects of the present disclosure can include methods of diagnosing a patient with a neuroendocrine carcinoma, methods of determining a survival prognosis in a patient diagnosed with a neuroendocrine carcinoma, compositions that effectively inhibits or decreases an expression level of a hepatocyte cell adhesion molecule 2 (HEPACAM2) biomarker in vivo or ex vivo, and methods of treating a patient having, or suspected of having, a neuroendocrine carcinoma.

A microfluidic device (12) for applying a sample of body fluid to a conditioned sensor element for the detection of molecular biomarkers in the body fluid and / or for conditioning the sensor element (14) using a conditioning fluid comprises at least one interaction chamber (40) that is partially closed by a sensor element (14). A pneumatic unit (70) is connected to the at least one first receptacle (46) and is configured to pressurize it and pump the body fluid or the conditioning fluid once and unidirectionally through the at least one interaction chamber (40) along the treated surface (16) and subsequently into the at least one disposal container (52), so that, in the case of body fluid, biomarkers adhere to the surface (16) or, in the case of conditioning fluid, the surface is conditioned.Furthermore, a biomarker detection device (18) and a method for applying a sample of body fluid to a conditioned sensor element (14) for biomarker detection and / or for conditioning a sensor element (14) for biomarker detection are proposed.

The invention provides an application technology for enabling early screening, early diagnosis and postoperative treatment judgment of gastric cancer by a multi-modal model algorithm, and belongs to the field of molecular biology, medical diagnosis and prevention. The method comprises the following steps: collecting a sample from human body liquid through a modern detection technology, detecting data of a plurality of molecular biomarkers and kit results associated with the gastric cancer or the cancer, and calculating by using a multi-modal model algorithm to find precancerous lesions, early gastric cancer or early cancer so as to reach the best early curing opportunity of a patient; the progression stage, pathological typing, clinical staging, metastatic state and postoperative curative effect inference of gastric cancer or cancer are analyzed and predicted, so that the cure effect of a patient can be improved and precise medical treatment can be realized in combination with a gastroscope pathological biopsy result; the sensitivity and the specificity precision of the kit approved by the country in the future are improved; the problem that early detection of medical early screening is difficult to solve is solved. The non-destructive detection and multi-modal model algorithm technology has wide usability, and has a demonstration effect on gastric cancer and other cancers.

Systems and methods for a wearable system that monitors various biomarkers with a 3D-printed wearable electronic skin. Specifically, the wearable system is a 3D-printed epidermal wearable microfluidic electronic skin that may be composed of a combination of multidimensional nanomaterials, polymers, and hydrogels. The epidermal wearable microfluidic electronic skin may be integrated with sensors, electrodes, microfluidics, and a processor to collect and analyze molecular biomarkers of biofluid samples on the user's skin, while simultaneously analyzing the user's physiological biomarkers to conduct a health status assessment or gather health monitoring / surveillance metric.

This invention relates to the pharmaceutical applications of MRPS7 as a diagnostic biomarker for non-small cell lung cancer (NSCLC) and its inhibitors, belonging to the field of biomedical technology. For the first time, this invention utilizes immunohistochemical analysis of tumor tissues from NSCLC patients and paired adjacent normal tissues to confirm that MRPS7 protein is significantly overexpressed in NSCLC tissues (p<0.001), and this difference is statistically significant in both lung adenocarcinoma and lung squamous cell carcinoma subtypes. Furthermore, this invention demonstrates through in vitro functional experiments that knocking down MRPS7 gene expression using siRNA targeting MRPS7 significantly inhibits the proliferation, migration, and invasion abilities of NSCLC cells (A549, SK-MES-1) (p<0.001). Therefore, reagents for detecting MRPS7 expression levels can be used to prepare NSCLC diagnostic products, and MRPS7 inhibitors can be used to prepare drugs for treating NSCLC. This invention provides a novel molecular biomarker for the diagnosis of NSCLC and a new strategy for targeted therapy of NSCLC.

Compositions, methods, and kits are provided for diagnosing vitreoretinal diseases and age-related pathologies. In particular, aqueous humor biomarkers have been identified that correlate with biological aging and age-related pathologies and morbidity. The use of such biomarkers may allow earlier intervention in treatment of aging-related diseases. In addition, methods of using aqueous humor biomarkers for prognosis, diagnosis, and monitoring treatment of vitreoretinal diseases are also provided.

Chronic Lung Allograft Dysfunction (CLAD) is characterized by a progressive and irreversible decline in lung function affecting half of lung transplant recipients within five years and is the major cause of death contributing to a low median post-transplant survival. Disclosed herein is an optimized airway inflammation gene set (AI2) and AI2 score, as well as RSI, RS2, and RS3 subscores, for use in methods of treating or preventing CLAD, methods of treating or preventing graft failure, methods of treating or preventing transplant rejection, methods of treating or preventing small airway fibrosis, methods of treating or preventing antibody mediated rejection (AMR) and methods of reducing mortality associated with graft failure. Also disclosed are methods of detecting or diagnosing CLAD and methods of predicting transplant rejection.

Molecular biomarkers relating to Fuchs' endothelial corneal dystrophy (FECD), glaucoma, and other degenerative ocular diseases are provided, as well as methods for using such biomarkers methods of treatment. These biomarkers may be used to monitor the progression of FECD, glaucoma, or other degenerative ocular diseases. Furthermore, these biomarkers may be used to monitor the treatment of FECD, glaucoma, or other degenerative ocular diseases.

This invention relates to the field of biomedical detection and molecular diagnostics, specifically to the application of KYAT1 protein and its modification sites as biomarkers in the preparation of products for the auxiliary diagnosis and prognostic assessment of breast cancer. The invention aims to reveal the positive correlation between high expression of the KYAT1 protein and the hydroxylation status of its proline at position 352 with the malignant biological behavior of breast cancer, and to use this as a molecular biomarker for the preparation of products to aid in the diagnosis of breast cancer or assess its perioperative prognostic risk.

The present invention provides devices and methods for detecting and capturing molecular biomarkers from a subject in situ. Specifically, the devices contain an array of microneedles to which are attached probes specific for one or more biomarkers of interest. The devices can be used directly on a subject (e.g., via skin piercing) in detecting the biomarkers in the body of the subject (e.g., tissues, blood stream).

The present disclosure relates generally to detection on non-coding RNAS molecules in a sample or diagnosis of subject based upon detection or quantification of non-coding nucleic acid sequences in a sample, specifically to identify and use of molecular biomarkers for cancer including breast cancer.

The invention belongs to the technical field of medical artificial intelligence, and particularly relates to a non-small cell lung cancer (NSCLC) prognosis prediction model integrating patient characteristics, clinical data and molecular markers, in particular to a prognosis prediction system for non-small cell lung cancer, which can be used for predicting prognosis conditions of patients and providing treatment suggestions. Firstly, the potential prognosis value of a serum biomarker clinically applied at present in pan cancer is systematically analyzed, clinical important characteristics such as age and gender are integrated, and a prognosis and curative effect prediction system for patients with lung cancer is established. According to the system, the survival risk of the NSCLC patient and the sensitivity of the patient to treatment can be accurately predicted, and making of a more accurate and efficient clinical decision is facilitated. The product has the advantages of low price, simple system operation, accurate prediction and the like, and has a very wide market prospect.

A method for detecting and quantifying analytes in a sample can include (a) identifying and / or profiling the analytes; (b) identifying at least one divider analyte from the analytes; (c) dividing the analytes into groups using the at least one divider analyte; and (d) detecting and / or quantifying a first group of analytes ending with a first divider analyte by scanning and / or quantifying the first group of analytes until a first threshold of intensity of the first divider analyte is reached. The method can further include (e) switching to detect and quantify a second group of analytes starting with the first divider analyte by scanning and quantifying the second group of analytes until a second threshold of intensity of a second divider analyte is reached. The step e) can be repeated until each group is scanned and / or quantified.

The invention discloses a method and a system for diagnosing and typing male infertility based on sperm RNA (Ribonucleic Acid) characteristics. The core of the invention lies in a biological discovery that most RNA can be systematically degraded and removed in the sperm maturation process, so that the total RNA content of healthy and mature sperms is in negative correlation with the functional soundness of the healthy and mature sperms. The method comprises the following steps: (a) obtaining a semen sample of a subject; (b) separating and purifying sperm cells from the sample; (c) quantifying the purified sperms, and determining the total RNA content of each sperm cell so as to obtain a first value; and (d) comparing the first numerical value with a preset reference value, and if the first numerical value is obviously higher than the reference value, indicating that the subject has low fertility or infertility (such as asthenospermia). According to the invention, an objective and quantifiable molecular biomarker is provided by quantifying residual'molecular package 'in the sperm maturation process, and a new way is provided for accurate diagnosis, typing and treatment of male infertility.

The invention relates to a microfluidic device (12) for applying a sample of a body fluid to a conditioned sensor element for the purposes of detecting molecular biomarkers in the body fluid and / or for conditioning the sensor element (14) by means of a conditioning fluid, the microfluidic device comprising at least one interaction chamber (40), some sections of which are closed by a sensor element (14). A pneumatic unit (70) is connected to the at least one first receptacle (46) and is designed to apply overpressure thereto and to pump the body fluid or the conditioning fluid through the at least one interaction chamber (40) along the treated surface (16) once and unidirectionally and then into the at least one disposal container (52), such that biomarkers adhere to the surface (16) in the case of body fluid, or the surface is conditioned in the case of conditioning fluid. The invention also relates to a biomarker detection device (18) and to a method for applying a sample of a body fluid to a conditioned sensor element (14) for the purposes of biomarker detection and / or for conditioning a sensor element (14) for the purposes of biomarker detection.

This invention discloses a molecular biomarker and kit for non-invasive early diagnosis and drug efficacy evaluation of lung adenocarcinoma. Specifically, this invention discloses the application of CpG islands of the PRSS3 gene as molecular biomarkers and / or substances for detecting the methylation level of said molecular biomarkers in the preparation of products for the treatment, diagnosis, or prognostic evaluation of non-small cell lung cancer. The molecular biomarker and its primers for detecting methylation status or level of this invention are characterized by high sensitivity and specificity; the kit based on detecting DNA sequence methylation within the PRSS3 gene can specifically detect PRSS3 gene-related DNA methylation levels, and can also specifically and quantitatively detect PRSS3 gene-related DNA methylation levels; the detection results can provide an evaluation method for monitoring the condition and individualized medication of non-small cell lung cancer patients, early tumor diagnosis, and prognostic assessment of drug treatment.